Objective: Here, we investigated whether a proinflammatory microbiota from Caspase1 −/− (Casp1 −/− ) mice accelerates atherogenesis in Ldlr −/− mice.
A therosclerosis, the main underlying cause of cardiovascular disease, is traditionally considered a lipid-driven disease. However, numerous studies have shown that atherosclerosis is influenced by the innate and adaptive immune system with cytokines involved in all stages of atherogenesis. 1, 2 Moreover, the CANTOS-trial (Canakinumab Antiinflammatory Thrombosis Outcomes Study) demonstrated that an antibody against IL (interleukin)-1β reduced recurrent cardiovascular events in patients with a previous myocardial infarction, indicating that inflammation enhances cardiovascular risk in humans. 3 Gut microbiota is known to be involved in the shaping of the immune system during early life. Recent studies have suggested a role for the gut microbiota in the regulation of inflammation by influencing differentiation of inflammatory cell types, cytokine production and hematopoiesis . [4] [5] [6] A leaky gut and alterations in gut microbiota composition can both lead to leakage of endotoxins into the circulation that promotes systemic inflammation and to the development of obesity and related metabolic diseases. 7, 8 Symptomatic atherosclerosis is associated with an altered gut metagenome in the human population, 9, 10 and bacterial DNA has been detected in atherosclerotic plaques. 11 Furthermore, a high blood concentration of the microbiota-dependent metabolite trimethyl-amine-N-oxide (TMAO) has been linked to an increased risk of atherosclerosis, [12] [13] [14] indicating a pivotal role for the gut microbiota in atherogenesis. In addition, germ-free ApoE-deficient (ApoE −/− ) mice showed lower circulating lipopolysaccharide levels, reduced systemic inflammation, and decreased atherogenesis compared with conventionally raised ApoE −/− mice. 15 Taken together, these findings suggest a triangular relationship between the gut microbiota, host immunity, and atherogenesis; however, proof to support a proinflammatory role for the gut microbiota in atherogenesis is lacking.
To examine whether introduction of a proinflammatory gut microbiota accelerates atherogenesis, we exposed female Ldlr −/− mice to the proinflammatory gut microbiota of Casp1 −/− mice, 7 as previous reports have demonstrated that alterations in their microbiota sensitize mice to the development of several inflammatory diseases. 7, 16 The gut microbiota of Casp1 −/− mice promoted atherosclerosis and increased blood leukocyte numbers, proinflammatory plasma cytokines, and neutrophil accumulation in atherosclerotic plaques, whereas plasma lipid and TMAO levels, and gut integrity were unaffected. The Casp1 −/− microbiota reduced microbiota-derived anti-inflammatory short-chain fatty acids (SCFAs).
Methods
The authors declare that all data supporting the findings of this study are available in its Online Data Supplement.
Results

Casp1 −/− Microbiota Successfully Introduced into Ldlr −/− Mice
To study whether a proinflammatory microbiota accelerates atherogenesis, we exposed antibiotic-treated Ldlr −/− mice to the gut microbiota of Casp1 −/− mice through fecal microbiota transplantation via a cohousing approach 7 ( Figure 1A ). Autologous transplantation of fecal microbiota from Ldlr −/− mice into antibiotic-treated Ldlr −/− mice via a cohousing approach 7 served as control. Analysis of fecal microbiota composition at time of sacrifice revealed both cohousing and diet-associated changes in gut microbial ecology ( Figure 1B 
Novelty and Significance
What Is Known?
• Atherosclerosis, the main underlying cause of cardiovascular disease, is influenced by both-the innate and adaptive immune systems. • Gut microbiota shape the immune system during early life and play a role in regulating inflammation by influencing the differentiation of inflammatory cell types, the production of cytokines, and hematopoiesis. • Inflammation and atherosclerosis are linked to changes in gut microbiota composition; however, there is little evidence to support a proinflammatory role of gut microbiota in atherosclerosis.
What New Information Does This Article Contribute?
• The presence of a proinflammatory microbiota derived from Caspase1 −/− (Casp1 −/− ) mice is sufficient to promote inflammation and atherosclerosis in antibiotic-treated Ldlr −/− mice, a mouse model with a human-like lipoprotein profile. • The gut microbiota of Casp1 −/− mice increases inflammation in antibiotic-treated Ldlr −/− mice, reflected by increased blood leukocyte numbers, particularly monocytes and neutrophils, proinflammatory plasma cytokines, and neutrophil accumulation in atherosclerotic plaques. • The gut microbiota of Casp1 −/− mice reduces the microbiota-derived anti-inflammatory short-chain fatty acids in antibiotic-treated Ldlr −/− mice, whereas plasma lipid, trimethylamine-N-oxide levels, and gut integrity are unaffected.
Several human studies have provided evidence that links the gut microbiota to cardiovascular disease. Nevertheless, the evidence supporting a causal role of the gut microbiota in cardiovascular disease is limited to the understanding of the importance of trimethylamine-N-oxide in atherogenesis. Recent findings suggest a pivotal role of the gut microbiota in regulating inflammation.
Here, we provide a novel, alternative mechanism by which the gut microbiota may contribute to atherogenesis, independent of plasma lipids and trimethylamine-N-oxide levels. We show that introduction of a proinflammatory gut microbiota into a mouse model with a human-like lipoprotein profile increases systemic inflammation and accelerates atherogenesis. This was associated with a reduction in microbiota-derived anti-inflammatory short-chain fatty acids, implying a causal relationship between microbiota composition, inflammation, and atherosclerosis. Collectively, these findings indicate that manipulation of the gut microbiota composition may be potentially effective treatment strategy to protect against inflammation and atherosclerosis and thereby reduce the risk of cardiovascular disease.
(referred to as Ldlr −/− [Casp1 −/− ] mice) and the Casp1 −/− donor mice ( Figure 1B ; Online Table II) . Analogously, we observed clustering between Ldlr −/− mice receiving the autologous microbiota transplantation (referred to as Ldlr −/− (Ldlr −/− ) mice) and their respective donor mice. We also observed a clear separation between mice fed chow or high-fat cholesterol (HFC) diet ( Figure 1B ; Online Table II) , and this was consistent for all donor and recipient mice. As expected, α-diversity was not different between Ldlr −/− (Ldlr −/− ) and Ldlr −/− (Casp1 −/− ) mice (Online Figure IB) . Altogether, these data demonstrate that Casp1 −/− and Ldlr −/− microbiota were successfully transferred into Ldlr −/− mice.
Casp1 −/− Dysbiosis Promotes Atherosclerosis in Ldlr −/− Mice Fed an HFC Diet
We analyzed atherosclerotic lesion size in the aortic root, and we found that Casp1 −/− microbiota did not affect atherosclerotic lesion size in Ldlr −/− mice fed chow or an HFC diet for 8 weeks (Figure 2A and 2B ). However, atherosclerotic lesion size was increased by 29% in Ldlr −/− (Casp1 −/− ) mice compared with Ldlr −/− (Ldlr −/− ) mice after 13 weeks of HFC feeding (Figure 2A and 2B; P<0.05). The collagen and macrophage content in aortic root sections was not different between the mice (Online Figure IIA) , indicating that lesion size but not severity was increased. In the aortic arches, gene expression of several macrophage-related and inflammatory markers was similar between HFC-fed mice with the exception of a significant increase in Il-10 expression in Ldlr −/− (C asp1 −/− ) mice (Online Figure IIB) . Body weight, plasma triglyceride, and cholesterol levels (Online Figure IIIA-IIID) also did not differ, and no alteration was observed in plasma levels of TMAO, its TMA precursors (choline, l-carnitine, betaine, and γ-butyrobetaine; Online Figure IIIE) , and TMAOproducing taxonomies (Online Figure IIIF) . Altogether, these results exclude plasma lipid levels and TMAO as factors that contribute to the increased atherosclerotic lesions in Ldlr −/− (C asp1 −/− ) mice.
Casp1 −/− Dysbiosis Promotes Inflammation
Next, we assessed whether Casp1 −/− dysbiosis accelerates atherosclerosis by increasing plasma inflammatory cytokines. We found a significant elevation in the plasma levels of IL-1β, IL-2, IL-10, and IFN (interferon)-γ in Ldlr −/− (Ca sp1 −/− ) mice after 13 weeks of HFC diet ( Figure 3A) , whereas CXCL1 (chemokine [C-X-C motif] ligand 1), TNF (tumor necrosis factor)-α, IL-5 and IL-6 were not affected (Online Figure IVB) . Flow cytometry analysis showed an increase in the number of blood Ly6C lo and Ly6C hi monocytes and neutrophils in Ldlr −/− (Casp1 −/− ) mice compared with Ldlr −/ − (Ldlr −/− ) mice accompanied by an increase in white blood cell count ( Figure 3B ; Online Figure IVA) , with leukocyte percentages being unchanged (Online Figure IVC) . We also observed increased neutrophil accumulation in atherosclerotic plaques of Ldlr −/− (Casp1 −/− ) mice compared with Ldlr −/ − (Ldlr −/− ) fed an HFC diet for 13 weeks ( Figure 3C and 3D) . These data suggest that Casp1 −/− dysbiosis enhances IL-1β plasma levels resulting in monocytosis and neutrophilia and increased neutrophil accumulation in atherosclerotic plaques.
Exposure to Casp1 −/− Microbiota Does Not Impair Intestinal Barrier Function in Ldlr −/− Mice Fed an HFC Diet
A disturbance in microbiota composition may affect intestinal integrity and subsequently promote systemic inflammation 7, 8 To investigate the effect of Casp1 −/− microbiota on intestinal barrier function, we analyzed the gut microbiota composition using the linear discriminant analysis (LDA) effect size (LEfSe) method. We identified 34 microbial taxonomies that differed in abundance between Ldlr −/− (Ldlr −/− ) and Ldlr −/− (Ca sp1 −/− ) mice (Online Figure VA) . Casp1 −/− dysbiosis resulted in a significant expansion of the genera Bilophila, Streptococcus, and Mucispirillum (Online Figure VB-VD) under both chowand HFC-diet conditions. Although these genera are associated with intestinal inflammation, and are known to expand under inflammatory conditions, 17 we did not observe any differences in intestinal barrier function, for example, inflammation and epithelial injury (Online Figure VIA-VIC) . In addition, mucus Figure VIG) . These results indicate that Casp1 −/− microbiota does not change the intestinal barrier function under HFC-diet conditions and, therefore, cannot explain the increase in plasma inflammatory cytokines.
Exposure to Casp1 −/− Microbiota Lowers SCFA-Producing Microbial Taxonomies and Cecum Concentration of SCFAs
We observed a significant reduction in the abundance of the SCFA-producing taxonomies Akkermansia (Figure 4A ), Christensenellaceae ( Figure 4B ), Clostridium ( Figure 4C ), and Odoribacter ( Figure 4D ) in Ldlr −/− (Casp1 −/− ) mice. As previous studies have shown that SCFAs reduce inflammation, 18, 19 we measured the concentrations of acetate, propionate, and butyrate in the cecum of the mice. Consistent with the lower abundance of SCFA-producing taxonomies, a significant reduction was observed in the cumulative levels of these SCFAs in Ldlr −/− (Casp1 −/− ) mice compared with Ldlr − /− (Ldlr −/− ) mice ( Figure 4E ) and this was mainly because of lower acetate levels in the Ldlr −/− (Casp1 −/− ) mice. Thus, it is conceivable that a reduction in the anti-inflammatory SCFAs may have contributed to the increased levels of inflammatory plasma cytokines of mice exposed to Casp1 −/− microbiota.
Discussion
We examined whether a proinflammatory microbiota accelerates atherogenesis in female Ldlr −/− mice, a mouse model exhibiting dyslipidemia, inflammation, and atherosclerosis, when fed a western style diet. 20 We found that Casp1 −/− microbiota increased atherosclerosis in the aortic root in HFC-fed Ldlr −/− mice ( Figure 1A and 1B) . This was accompanied by increased proinflammatory plasma cytokines ( Figure 3A) , increased blood leukocyte numbers, particularly monocytes and neutrophils ( Figure 3B ), increased neutrophil accumulation in atherosclerotic plaques ( Figure 3C and 3D) , and reduced levels of SCFAs in the cecum ( Figure 4E) . These results imply a causal relationship between microbiota composition, inflammation, and atherosclerosis. We found that in particular the plasma levels of IFN-γ, IL-2, and IL-1β were increased in Ldlr −/− mice with Casp1 −/− dysbiosis, suggesting that accelerated atherosclerosis in these mice is partially driven by these cytokines, which is supported by previous studies. [21] [22] [23] Furthermore, we showed an increase in peripheral blood leukocytes, which have previously been linked to cardiovascular disease. 24 Within the leukocyte population, neutrophils and monocytes are important contributors to atherogenesis. 25 Increased monocytes and neutrophils in the circulation may lead to infiltration of monocytes and neutrophils into atherosclerotic plaques and further promoting plaque growth. 25 We observed that exposure to Casp1 −/− microbiota lowers SCFA-producing taxonomies and cumulative cecum concentrations of SCFAs. SCFAs have anti-inflammatory properties and can suppress NF-κB (nuclear factor κB) activity in immune cells, 18 resulting in reduced production of proinflammatory cytokines including IFN-γ, IL-1β, and IL-2. 26 Furthermore, SCFAs may act as modulators of immune homeostasis by acting as HDAC (histone deacetylase) inhibitors. 19 Oral butyrate supplementation has recently been shown to attenuate the adhesion and migration of macrophages and to decrease proinflammatory cytokines in atherosclerotic plaques. 27 Thus, it is tempting to speculate that the reduction in SCFAs in Ldlr −/− mice after exposure to Casp1 −/− microbiota may have contributed to increased levels of proinflammatory cytokines and leukocytes in the circulation and neutrophil accumulation in the atherosclerotic plaque.
It is well recognized that microbial transplantation can be transient. 13 Thus, we cannot exclude that certain effects on TMAO, although not present at time of sacrifice, may have been lost throughout the length of the study. In line with this, the possibility exists that the inflammatory effects may have been dampened over time. Future studies, therefore, should include more frequent and earlier time points to rule out these possibilities.
Whereas previous studies have shown a decreased abundance of Akkermansia muciniphila on high-fat diet feeding, our data show on opposing effect on A muciniphila after HFC feeding. A similar effect on high-fat and high-carbohydrate diet feeding in mice was recently shown 28 and warrants further investigation. Nevertheless, promising results have been obtained with the administration of A muciniphila resulting in protection against atherogenesis in ApoE −/− mice by strengthening the gut barrier and preventing metabolic endotoxemiainduced inflammation. 29 Likewise, metformin's reported beneficial effects on atherosclerosis in humans with type I and II diabetes mellitus and nondiabetic dysglycaemia may be related to its ability to enhance the growth of A muciniphila and promote SCFA production. 30 Together with our findings, this indicates that manipulation of the gut microbiota composition is an interesting treatment strategy to protect against inflammation and atherosclerosis and reduce cardiovascular disease risk. 
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